tetano
Editor, Senior Moderator
Commun Biol
. 2023 Jun 1;6(1):592.
doi: 10.1038/s42003-023-04955-3. A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
Fanlin Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Wei Xu[SUP] #[/SUP][SUP] 3 [/SUP], Xiaoqing Zhang[SUP] #[/SUP][SUP] 1 4 [/SUP], Wanting Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shan Su[SUP] 3 [/SUP], Ping Han[SUP] 1 2 [/SUP], Haiyong Wang[SUP] 1 2 [/SUP], Yanqin Xu[SUP] 1 2 [/SUP], Min Li[SUP] 1 2 [/SUP], Lilv Fan[SUP] 1 2 [/SUP], Huihui Zhang[SUP] 1 2 [/SUP], Qiang Dai[SUP] 1 2 [/SUP], Hao Lin[SUP] 1 2 [/SUP], Xinyue Qi[SUP] 1 2 [/SUP], Jie Liang[SUP] 1 2 [/SUP], Xin Wang[SUP] 5 [/SUP], Shibo Jiang[SUP] 3 [/SUP], Youhua Xie[SUP] 6 [/SUP], Lu Lu[SUP] 7 [/SUP], Xuanming Yang[SUP] 8 9 [/SUP]
Affiliations
Neutralizing antibodies exert a potent inhibitory effect on viral entry; however, they are less effective in therapeutic models than in prophylactic models, presumably because of their limited efficacy in eliminating virus-producing cells via Fc-mediated cytotoxicity. Herein, we present a SARS-CoV-2 spike-targeting bispecific T-cell engager (S-BiTE) strategy for controlling SARS-CoV-2 infection. This approach blocks the entry of free virus into permissive cells by competing with membrane receptors and eliminates virus-infected cells via powerful T cell-mediated cytotoxicity. S-BiTE is effective against both the original and Delta variant of SARS-CoV2 with similar efficacy, suggesting its potential application against immune-escaping variants. In addition, in humanized mouse model with live SARS-COV-2 infection, S-BiTE treated mice showed significantly less viral load than neutralization only treated group. The S-BiTE strategy may have broad applications in combating other coronavirus infections.
. 2023 Jun 1;6(1):592.
doi: 10.1038/s42003-023-04955-3. A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
Fanlin Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Wei Xu[SUP] #[/SUP][SUP] 3 [/SUP], Xiaoqing Zhang[SUP] #[/SUP][SUP] 1 4 [/SUP], Wanting Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shan Su[SUP] 3 [/SUP], Ping Han[SUP] 1 2 [/SUP], Haiyong Wang[SUP] 1 2 [/SUP], Yanqin Xu[SUP] 1 2 [/SUP], Min Li[SUP] 1 2 [/SUP], Lilv Fan[SUP] 1 2 [/SUP], Huihui Zhang[SUP] 1 2 [/SUP], Qiang Dai[SUP] 1 2 [/SUP], Hao Lin[SUP] 1 2 [/SUP], Xinyue Qi[SUP] 1 2 [/SUP], Jie Liang[SUP] 1 2 [/SUP], Xin Wang[SUP] 5 [/SUP], Shibo Jiang[SUP] 3 [/SUP], Youhua Xie[SUP] 6 [/SUP], Lu Lu[SUP] 7 [/SUP], Xuanming Yang[SUP] 8 9 [/SUP]
Affiliations
- PMID: 37264086
- DOI: 10.1038/s42003-023-04955-3
Neutralizing antibodies exert a potent inhibitory effect on viral entry; however, they are less effective in therapeutic models than in prophylactic models, presumably because of their limited efficacy in eliminating virus-producing cells via Fc-mediated cytotoxicity. Herein, we present a SARS-CoV-2 spike-targeting bispecific T-cell engager (S-BiTE) strategy for controlling SARS-CoV-2 infection. This approach blocks the entry of free virus into permissive cells by competing with membrane receptors and eliminates virus-infected cells via powerful T cell-mediated cytotoxicity. S-BiTE is effective against both the original and Delta variant of SARS-CoV2 with similar efficacy, suggesting its potential application against immune-escaping variants. In addition, in humanized mouse model with live SARS-COV-2 infection, S-BiTE treated mice showed significantly less viral load than neutralization only treated group. The S-BiTE strategy may have broad applications in combating other coronavirus infections.